Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach

por Grant, A, Kamuntu, Y, Read, P, Kulasegaram, R
Publicado 2010

Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co-infected patients

por Surah, S, Samarawickrama, A, Campbell, L, Kulasegaram, R, Post, F, Fisher, M, Peters, B, Fox, J
Publicado 2010

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study

por Aboud, M, Elgalib, A, Pomeroy, L, Panayiotakopoulos, G, Skopelitis, E, Kulasegaram, R, Dimian, C, C Lampe, F, Duncan, A, Wierzbicki, A S, Peters, B S
Publicado 2010